ascopubs.org

OPTIMAS: A phase II randomized, decentralized, de-escalation trial in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.

A phase I clinical trial of autologous gamma delta T cells genetically engineered with a chimeric receptor to target the prostate stem cell antigen in patients with metastatic castration-resistant ...
IEEE

A Data-Driven Real-Time Optimal Power Flow Algorithm Using Local Feedback in Distribution Networks

Abstract: The increasing penetration of distributed energy resources (DERs) adds variability as well as fast control capabilities to power networks. Dispatching the DERs based on local information to ...
IEEE

PS-ECBS: A New Algorithm for Multi-Agent Path Finding With Optimal Task Assignment

Abstract: Multi-agent path finding (MAPF) problem in warehouse automation consists of optimal task assignment and path planning, where small runtime is necessary. In this letter, we present a new MAPF ...
ahajournals.org

Frailty Index Offers Greater Discrimination Than Age for Optimal Blood Pressure Targets: A Pooled Analysis of Two Randomized Trials

Department of Epidemiology and Health Statistics, School of Public Health, Xi’an Jiaotong University Health Science Center, Xi’an, Shaanxi, China (Yizhen Lyu, W.B ...
UroToday

ASCO GU 2026: OPTIMAS: A Phase II Randomized, Decentralized, De-Escalation Trial in Patients with mHSPC Achieving Optimal PSA Response

(UroToday.com) The 2026 ASCO GU Annual Symposium was host to a trials-in-progress prostate cancer poster session. Dr. Umang Swami presented OPTIMAS, an ongoing randomized, decentralized, de-escalation ...
UroToday

ASCO GU 2026: Dose Optimization and PSMA Receptor Intensification with 177Lu-PSMA-597 in mCRPC: The Randomized Phase II OPTIMAL-PSMA Trial

(UroToday.com) The 2026 ASCO GU Annual Symposium was host to a trials-in-progress prostate cancer poster session. Dr. Louise Emmett presented OPTIMAL-PSMA, an ongoing randomized phase II trial that is ...